A Comparative Docking Analysis of Remdesivir and Dexamethasone Efficacy on Patients with COVID-19 and Myasthenia gravis

ABSTRACT

The treatment of patients having Myasthenia gravis and COVID-19 is a new domain for scientific research wherein a standard model is yet to be firmly established due to the dynamic nature of the development of the two diseases in the patients. Based on a few reports obtained, one study involved the application of Dexamethasone and Remdesivir in a measured dosage. The main drug of interest for this study was Dexamethasone because of its innate nature of acting as an immunosuppressive agent which helps combating the cytokine storms which is known to cause severe respiratory issues in COVID-19 affected patients. This drug, however, does not tackle the root problem. To target the virus, Remdesivir is chosen. The results seen are in agreement with our observations which indicate that for the overall improvement in patient health to be seen a combination of the both these drugs along with other support systems need to be taken in order to ensure overall improvement in patient recovery.Based on the observed binding affinities, improved drugs can be made. © The Electrochemical Society